U.S. Markets close in 2 hrs 19 mins

Are Insiders Buying Antibe Therapeutics Inc. (CVE:ATE) Stock?

Simply Wall St

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So shareholders might well want to know whether insiders have been buying or selling shares in Antibe Therapeutics Inc. (CVE:ATE).

Do Insider Transactions Matter?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, most countries require that the company discloses such transactions to the market.

Insider transactions are not the most important thing when it comes to long-term investing. But logic dictates you should pay some attention to whether insiders are buying or selling shares. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

See our latest analysis for Antibe Therapeutics

Antibe Therapeutics Insider Transactions Over The Last Year

While no particular insider transaction stood out, we can still look at the overall trading.

Over the last year, we can see that insiders have bought 346.67k shares worth CA$103k. On the other hand they divested 120000 shares, for CA$53k. In the last twelve months there was more buying than selling by Antibe Therapeutics insiders. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

TSXV:ATE Recent Insider Trading, December 15th 2019

Antibe Therapeutics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Antibe Therapeutics Insiders Are Selling The Stock

The last three months saw some Antibe Therapeutics insider selling. Independent Director Roderick Flower only netted CA$53k selling shares, in that period. Neither the lack of buying nor the presence of selling is heartening. But the volume sold is so low that it really doesn't bother us.

Does Antibe Therapeutics Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 5.9% of Antibe Therapeutics shares, worth about CA$7.1m, according to our data. But they may have an indirect interest through a corporate structure that we haven't picked up on. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Does This Data Suggest About Antibe Therapeutics Insiders?

An insider sold Antibe Therapeutics shares recently, but they didn't buy any. On the other hand, the insider transactions over the last year are encouraging. Still, insiders don't own a great deal of the stock. So we can't be sure that insiders are optimistic. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

But note: Antibe Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.